Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Versant Ventures

Investor type Venture Capital
Founders Barbara Lubash Brian Atwood Donald B. Milder Rebecca Robertson Samuel Colella William Link

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 361
Average round size
info
The average size of a deal this fund participated in
$33M
Portfolio companies 172
Rounds per year 15.70
Lead investments 49
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.52
Exits 90
Key employees 13
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Therapeutics
Summary

In 1999 was created Versant Ventures, which is appeared as VC. The main office of represented VC is situated in the Menlo Park. The fund was located in North America if to be more exact in United States.

The current fund was established by Barbara Lubash, Brian Atwood, Donald B. Milder, Rebecca Robertson, Samuel Colella, William Link. Besides them, we counted 13 critical employees of this fund in our database.

Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The average startup value when the investment from Versant Ventures is 50-100 millions dollars. The important activity for fund was in 2008. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 13-24 deals every year. This Versant Ventures works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2018.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Versant Ventures, startups are often financed by OrbiMed, Investor Growth Capital Limited, Frazier Healthcare Partners. The meaningful sponsors for the fund in investment in the same round are Pequot Capital, Novartis Venture Fund, Kleiner Perkins. In the next rounds fund is usually obtained by Kleiner Perkins, Novartis Venture Fund, Abingworth.

Among the most popular portfolio startups of the fund, we may highlight Audentes Therapeutics, Pharmion, Kythera Biopharmaceuticals. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Medical Device, Life Science.

Read more

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Jnana

Biotechnology
Health Care
Therapeutics
$107M15 Nov 2022 Boston, Massachusetts, United States

Vector BioPharma

Biotechnology
Life Science
$30M10 Aug 2022 Basel, Basel-Stadt, Switzerland

Tempest Therapeutics

Biotechnology
Health Care
Therapeutics
$15M27 Apr 2022 San Francisco, California, United States

Cimeio Therapeutics

Biopharma
Biotechnology
Health Care
Medical
$50M13 Apr 2022 Basel, Basel-Stadt, Switzerland

Ventus Therapeutics

Biotechnology
Life Science
$140M09 Feb 2022 Massachusetts, United States

Nested Therapeutics

Health Care
Health Diagnostics
Medical
Medical Device
$35M01 Jan 2022 Cambridge, Massachusetts, United States

CODA Biotherapeutics

Biotechnology
Therapeutics
$28M02 Dec 2021 South San Francisco, California, United States

SanReno Therapeutics

Biotechnology
Therapeutics
$40M30 Nov 2021 Beijing, Beijing, China

ViaLase

Health Care
Medical Device
Wellness
$27M19 Nov 2021 Corona Del Mar, California, United States
News
858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

– 858 Therapeutics has raised $60m in Series A financing.
– The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
– 858 is a biotechnology company developing novel therapeutics for the treatment of cancer.
– The company’s lead program is a novel small molecule inhibitor of the PI3K/mTOR pathway that is being developed for the treatment of solid tumors that are resistant to existing therapies.
– The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies.

iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases

– iECURE (pronounced EE-ah-cure), a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, announced it has closed a $50m Series A financing led by Versant Ventures and OrbiMed Advisors.
– The funds will be used to advance iECURE’s pipeline of up to 13 programs, all of which benefit from gene editing and in vivo delivery approaches being developed in the laboratory of James Wilson, M.D., Ph.D., of the University of Pennsylvania Gene Therapy Program (GTP).
– iECURE’s approach focuses on the mutation-agnostic in vivo insertion of healthy copies of disease-causing genes, with an initial focus in liver disorders.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Versant Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: